Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Pharma-Bio Serv (PBSV) Revenue (2016 - 2026)

Pharma-Bio Serv filings provide 16 years of Revenue readings, the most recent being $2.3 million for Q1 2026.

  • On a quarterly basis, Revenue fell 7.14% to $2.3 million in Q1 2026 year-over-year; TTM through Jan 2026 was $8.8 million, a 8.08% decrease, with the full-year FY2025 number at $9.0 million, down 5.34% from a year prior.
  • Revenue hit $2.3 million in Q1 2026 for Pharma-Bio Serv, up from $2.1 million in the prior quarter.
  • In the past five years, Revenue ranged from a high of $5.0 million in Q1 2022 to a low of $2.0 million in Q3 2025.
  • Median Revenue over the past 5 years was $2.5 million (2025), compared with a mean of $3.4 million.
  • Biggest five-year swings in Revenue: rose 11.83% in 2022 and later crashed 47.9% in 2024.
  • Pharma-Bio Serv's Revenue stood at $4.6 million in 2022, then decreased by 22.42% to $3.6 million in 2023, then crashed by 35.15% to $2.3 million in 2024, then dropped by 7.87% to $2.1 million in 2025, then increased by 6.76% to $2.3 million in 2026.
  • The last three reported values for Revenue were $2.3 million (Q1 2026), $2.1 million (Q4 2025), and $2.0 million (Q3 2025) per Business Quant data.